NTCOC
RIGL icon

Northern Trust Company of Connecticut’s Rigel Pharmaceuticals RIGL Stock Holding History

Northern Trust Company of Connecticut’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$4K Hold
152
– – ﹤0.01% 2006
2013
Q3 		$5K Hold
152
– – ﹤0.01% 1981
2013
Q2 		$5K Buy
+152
New +$6.89K ﹤0.01% 1962

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Northern Trust Company of Connecticut's RIGL Position: Q4 2013 in Review

Northern Trust Company of Connecticut held its Rigel Pharmaceuticals (RIGL) position steady in Q4 2013 at 152 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #2006.

Northern Trust Company of Connecticut first reported a position in RIGL in Q2 2013 and has held it in 3 quarters since. The position peaked at $5K in Q3 2013. 100 funds tracked by Wall St. Rank hold RIGL as of Q4 2013.

  • Northern Trust Company of Connecticut held 152 shares of Rigel Pharmaceuticals worth $4K as of Q4 2013.
  • Northern Trust Company of Connecticut left its Rigel Pharmaceuticals share count unchanged in Q4 2013.
  • Rigel Pharmaceuticals made up ﹤0.01% of Northern Trust Company of Connecticut's portfolio in Q4 2013, its #2006 holding.
  • Northern Trust Company of Connecticut first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 3 quarters since.
  • Northern Trust Company of Connecticut's Rigel Pharmaceuticals position peaked at $5K in Q3 2013.
  • 100 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.